Neuralstem Treats 18th Patient and Concludes Phase I Clinical Trial

Neuralstem, Inc. just treated their 18th and final patient in their Phase I ALS clinical trial. The goal of the Phase I study was to determine if Neuralstem’s stem cell therapy was safe to inject into the spinal cords of patients. The results of this initial study are promising. Dr. Eva Feldman, the lead investigator of the trial, commented, “In some patients, it appears that [ALS] is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful.” If the stem cell therapy is deemed safe by the FDA, Neuralstem will begin enrolling for their Phase II clinical trial.

Click here to read more.

Share this: